Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Authors: Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne, Mehdi Brahmi, Nicolas Penel, Sophie Cousin, François Bertucci, Emmanuelle Bompas, Thomas Ryckewaert, Pauline Soibinet, Pascaline Boudou‐Rouquette, Esma Saada Bouzid, P Soulié, Thibaud Valentin, Jean‐Pierre Lotz, Diégo Tosi, Zoé Nevière, Mathilde Cancel, Isabelle Ray‐Coquard, Laëtitia Gambotti, Frédéric Legrand, Assia Lamrani-Ghaouti, Clotilde Simon, Caroline Even, Christophe Massard - The Lancet 2023 cited by 88